Certain bulk drug substances for use in compounding that may present significant safety risks
Regulatory source for compounding-safety watch items; status should be rechecked before publication.
Evidence memo
Epitalon
Also tracked as: Epithalon, Epithalone
A telomerase and aging-claim peptide where mechanistic narratives outrun independently replicated human outcome evidence.
Safety/regulatory watch Safety watch
Evidence status
High interest / low certainty. Evidence level: Safety/regulatory watch.
Claim being evaluated
Whether telomere and circadian claims translate into validated human healthspan or disease-outcome benefits.
Why people care
The telomerase story is compelling, but it is easy to overstate because aging biomarkers are not the same as clinical outcomes.
Signal so far
The evidence base includes mechanistic and regional clinical literature, but independent, modern, well-controlled outcome evidence is limited.
Biggest unknown
Replication quality, endpoint validity, long-term safety, and product identity.
Safety/regulatory boundary
Mechanistic plausibility is not clinical proof, and telomerase narratives require special caution.
Watch next
Independent trial registration, reproducible outcome data, and regulatory updates.
Evidence interpretation
A good example of why the Watchlist separates biological plausibility from clinical proof.